ALLMedicine™ Extranodal Lymphoma Center

Mar 14th, 2023 - Practice Essentials Necrotizing sialometaplasia (NS) is a nonneoplastic inflammatory condition of the salivary glands. In 1973, Abrams et al first reported this condition. [1] The clinical and histopathologic features of necrotizing sialometaplasi...

Mar 14th, 2023 - Practice Essentials Necrotizing sialometaplasia (NS) is a nonneoplastic inflammatory condition of the salivary glands. In 1973, Abrams et al first reported this condition.[1] The clinical and histopathologic features of necrotizing sialometaplasia...

Mar 14th, 2023 - Practice Essentials Necrotizing sialometaplasia (NS) is a nonneoplastic inflammatory condition of the salivary glands. In 1973, Abrams et al first reported this condition. [1] The clinical and histopathologic features of necrotizing sialometaplasi...

Mar 3rd, 2023 - In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by 18F-FDG PET (PET/CT and PET/MR). Prior to treatment, all patients will undergo whole-body 18F-FDG PET/CT and PET/MR. The methods' efficiency was compared in the ...

Mar 3rd, 2023 - In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by different molecular probe such as FDG, FAPI-04 via multimodality PET (PET/CT and PET/MR). Our Previous studies have shown that uptake of FAPI-04 on PET may be an...

Mar 2nd, 2019 - Primary extranodal non-Hodgkin's lymphomas (EN-NHL) are a heterogeneous group of malignancies that involve numerous entities with significant difference in terms of tumor site locations, prognostic factors, biology expression, and therapeutic opti...

Mar 3rd, 2023 - In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by 18F-FDG PET (PET/CT and PET/MR). Prior to treatment, all patients will undergo whole-body 18F-FDG PET/CT and PET/MR. The methods' efficiency was compared in the ...

Mar 3rd, 2023 - In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by different molecular probe such as FDG, FAPI-04 via multimodality PET (PET/CT and PET/MR). Our Previous studies have shown that uptake of FAPI-04 on PET may be an...

Dec 22nd, 2021 - Primary central nervous system lymphoma (PCNSL) is a rare extranodal non-hodgkin's lymphoma confined to the central nervous system. It accounts for about 4% of all intracranial tumors and 4% to 6% of all non-Hodgkin's lymphomas . Among them, the m...

Aug 7th, 2019 - Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare presentation of non-Hodgkin's lymphoma. A significant risk of contralateral breast involvement and a tendency for central nervous system (CNS) progression have been identified in previ...

Jul 21st, 2015 - Introduction Extranodal marginal zone B-cell lymphoma (MZBL) of the mucosa associated lymphoid tissue (MALT-lymphoma) is the most common form of extranodal lymphoma [1, 2]. Although MALT-lymphoma may involve different organs, the stomach represent...

Jun 29th, 2022 - The addition of orelabrutinib (ICP-022) to sintilimab demonstrated good efficacy with a rapid time to response (TTR) in patients with relapsed/refractory (R/R) primary central nervous system lymphoma (PCNSL), according to findings from a phase 2 s...

Dec 9th, 2021 - Key Takeaway Sarcopenia measured by temporalis muscle thickness (TMT) robustly and independently predicts early relapse and short survival in primary central nervous system (CNS) lymphoma. Very thin TMT is a better predictor of mortality than the ...

Sep 2nd, 2021 - Primary central nervous system lymphoma (PCNSL) is a rare and aggressive variant of extranodal non-Hodgkin lymphoma (NHL) that occurs in the brain, spinal cord, cerebrospinal fluid (CSF), or eyes in the absence of systemic disease. Although it res...

Dec 20th, 2020 - Andrés Ferreri, MD The MATRIX regimen, comprised of a methotrexate/cytarabine backbone plus thiotepa and rituximab, improved outcomes in patients with primary CNS lymphoma, according to results from the international randomized phase II ELSG #3...

Jun 24th, 2015 - Palazzo Dei Congressi, site of 13-ICML LUGANO—Adding thiotepa and rituximab to the treatment of primary central nervous system (CNS) lymphoma is feasible from a safety perspective and has yielded promising results, according to new research. An an.